Healthcare Services company Vimta Labs announced Q1FY26 results Total Income for Q1FY26 was at Rs 993 million. EBITDA for Q1FY26 was Rs 354 million; EBITDA margin was at 35.7%. PBT for Q1FY26 was at Rs 253 million. Q1FY26 PAT was at Rs 189 million; PAT margin was at 19.0% Basic EPS in Q1FY26 was Rs 4.2 Harita Vasireddi, Managing Director, Vimta Labs , said: “We are happy to report a revenue of Rs 993 million for the quarter which was driven by pharmaceutical & food contract research and testing services that we provide. I am pleased with the consistent progress Vimta continues to make in strengthening its service portfolio and deepening customer relationships across sectors. Vimta completes a successful USFDA GCP inspection with zero Form 483 observations and received letter of cGMP compliance from ANSM (EMA) during the quarter. These outcomes are a reflection of Vimta's strong commitment to quality, and scientific rigor. As a part of our efforts to enhance shareholder value, the Board has approved a Bonus issue in the ratio of 1:1, showcasing the company's strong financial position, confidence in future growth, and commitment to rewarding its shareholders. Our focus remains on expanding our market reach and capabilities, fostering innovation, and creating sustainable long-term value for all our stakeholders.” Result PDF
Healthcare Services company Vimta Labs announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Total Income for Q4FY25 was at Rs 961 million. EBITDA for Q4FY25 was Rs 347 million; EBITDA margin was at 36.1%. PBT for Q4FY25 was at Rs 250 million. Q4FY25 PAT* was at Rs 183 million; PAT margin was at 19.1%. Basic EPS in Q4FY25 was Rs 8.2. FY25 Financial Highlights: Total Income for FY25 was at Rs 3,482 million. EBITDA for FY25 was Rs 1,262 million; EBITDA margin was at 36.2%. PBT for FY25 was at Rs 890 million. FY25 PAT* was at Rs 668 million; PAT margin was at 19.2%. Basic EPS in FY25 was Rs 30. Total Debt as of 31 st March 2025 stood at Rs 85 million. Cash and Cash equivalents including bank balance stood at Rs 329 million as of 31 st March 2025. Harita Vasireddi, Managing Director, Vimta Labs, said: "We are pleased to report strong earnings and good growth this year, driven by growth in pharmaceutical services. Our pharma business benefited from increased traction in clinical and analytical services, supported by capacity expansion and deeper client engagements. Our continued investments in talent, infrastructure, and business development are strengthening our platform for long-term value creation. We are excited to announce our entry into Biologics Contract R&D; services, a strategic move that aligns with the future of healthcare and enhances our capabilities across the biopharma value chain. This initiative will enable Vimta to offer end-to-end support for biologics development, reinforcing our position as a trusted partner in high-quality, science-driven innovation. We remain committed to scaling our capabilities, driving innovation, and delivering long-term value for our stakeholders.” Result PDF
Healthcare Services company Vimta Labs announced 9MFY25 & Q3FY25 results Q3FY25 Financial Highlights: Total Income for Q3FY25 was at Rs 911 million. EBITDA for Q3FY25 was Rs 343 million; EBITDA margin was at 37.6%. PBT for Q3FY25 was at Rs 239 million. Q3FY25 PAT was at Rs 175 million; PAT margin was at 19.2%. Basic EPS in Q3FY25 was Rs 7.9. 9MFY25 Financial Highlights: Total Income for 9MFY25 was at Rs 2,521 million. EBITDA for 9MFY25 was Rs 915 million; EBITDA margin was at 36.3%. PBT for 9MFY25 was at Rs 640 million. 9MFY25 PAT was at Rs 484 million; PAT margin was at 19.2%. Basic EPS in 9MFY25 was Rs 21.8. Total Debt as of 31st December 2024 stood at Rs 113 million. Cash and Cash equivalents including bank balance stood at Rs 180 million as of 31st December 2024. Harita Vasireddi, Managing Director, Vimta Labs, said: "We are happy to report that Vimta Labs had another successful quarter with a strong growth of 21.1% YoY. This was mainly pushed by the Drug Development & Discovery Services. EBITDA margin for the quarter stood at 37.6% which is a growth of 496 bps on a YoY basis. During the quarter, our new addition to the Life Sciences Facility, was commercialised which has helped ease our operations giving us the space to work more efficiently. As we look to the future, we remain optimistic about our strategic direction and the robustness of our service offerings, which we believe will drive sustained growth and success.” Result PDF
Healthcare Services company Vimta Labs announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Total Income for Q2FY25 was at Rs 854 million. EBITDA for Q2FY25 was Rs 306 million; EBITDA margin was at 35.8%. PBT for Q2FY25 was at Rs 219 million. Q2FY25 PAT was at Rs 170 million; PAT margin was at 19.9%. Basic EPS in Q2FY25 was Rs 7.7. H1FY25 Financial Highlights: Total Income for H1FY25 was at Rs 1,610 million. EBITDA for H1FY25 was Rs 572 million; EBITDA margin was at 35.5%. PBT for H1FY25 was at Rs 401 million. H1FY25 PAT was at Rs 309 million; PAT margin was at 19.2%. Basic EPS in H1FY25 was Rs 13.9. Total Debt as of 30th September 2024 stood at Rs 116 million. Cash and Cash equivalents including bank balance stood at Rs 278 million as of 30th September 2024. Harita Vasireddi, Managing Director, Vimta Labs, said: "We are pleased to report a strong operational performance for Q2FY25, with revenues of Rs 854 million, reflecting a 26.4% YoY growth. Our EBITDA rose by 57.3% YoY, and net profit surged by 109.9%. This performance was primarily driven by our pharmaceutical services, which continue to lead the business. As stated in our August 30, 2024, press release, Vimta Labs has divested the Diagnostic and Pathological services business to Thyrocare Technologies. This decision allows us to sharpen our focus on core services and optimize resources for sustained growth, resulting in a significant improvement in our EBITDA margins, which now exceed 35%, up from the previous range of 23% to 30%. Looking ahead, our Pharmaceutical services continue to show promising growth, and we anticipate that our food testing services will also contribute to growth in coming quarteRs We are also expanding our electrical and electronics testing capabilities and preparing to commission a new facility in couple of quarteRs We remain committed to driving sustainable and impactful growth for our investors.” Result PDF